Rosenberg, June and Allison share 2018 Albany Prize

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Steven Rosenberg
Carl June
James Allison

Steven Rosenberg, Carl June and James Allison received the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.

  • Rosenberg is chief of the surgery branch at NCI.

  • June is director of the Center for Cellular Immunotherapy at the Abramson Cancer Center at the University of Pennsylvania.

  • Allison is chair of the Department of Immunology at MD Anderson Cancer Center.

The $500,000 award has been given annually since 2001 to “those who have altered the course of medical research.”

A statement from the Albany Medical Center said the ”awardees were chosen to receive the 2018 Albany Prize for their groundbreaking research in immunology, the translation of their ideas into clinically meaningful therapies for diseases, including metastatic melanoma, lung cancer and leukemia, and their leadership in moving the field of immunotherapy forward.”

“We congratulate these amazing scientists for receiving this prestigious award. Their visionary work exemplifies the value of the national cancer program. Each has had a long history of NCI support and I celebrate their achievement,” NCI Director Ned Sharpless said in a statement. “Dr. Rosenberg is a pioneer whose immunotherapy work has advanced cancer treatment to an immeasurable degree. His innovations have changed patients’ lives.”

Vincent Verdile, the Lynne and Mark Groban Distinguished Dean of Albany Medical College and chair of the Albany Prize National Selection Committee, said that “because of the work of these three researchers, the nascent field of immunotherapy has already had spectacular success, leading to effective mitigation and often cures for thousands of cancer and HIV patients whose diseases were not treatable by other methods.”

The prize will be awarded during a celebration on Sept. 26, in Albany.

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login